Development of small molecules for the treatment of Type 2 diabetes
Location: France, Auvergne-Rhône-Alpes, Lyon
Employees: 51-200
Total raised: $36.44M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | Andera Par... | anderapart... |
| - | Omnes Capi... | omnescapit... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.05.2020 | - | $19.31M | - |
| 21.12.2012 | Series B | $17.13M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 19.07.2016 | Postponing Nasdaq IPO, Poxel raises €26.5M to move diabetes ... | Poxel (EPA:POXEL) has hit pause on its plan to file for an IPO on Nasdaq. The Merck Serono spinout i... | fiercebiot... |
| 21.12.2012 | Poxel Closes €13M Series B Funding | Poxel SA, a Lyon, France-based biopharma startup developing drugs with a primary focus on Type 2 dia... | finsmes.co... |
| 18.12.2012 | Poxel SA Raises $17M Series B | LYON, FRANCE, Poxel SA announces today, that it has raised EUR13 million (USD 17 million) in a Ser... | vcnewsdail... |
| 08.07.2010 | Poxel Raises €16M in Series A Financing | Poxel S.A., a Lyon, France-based diabetes drug development specialist and a spin off from Merck Sero... | finsmes.co... |